Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60–8.

Article  PubMed  Google Scholar 

Collaborators. GDaIIaP. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1545–602.

Article  Google Scholar 

Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, burden, and comorbidity. Neurol Clin. 2019;37:631–49.

Article  PubMed  Google Scholar 

Blumenfeld AM, Bloudek LM, Becker WJ, Buse DC, Varon SF, Maglinte GA, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: results from the second international burden of migraine study (IBMS-II). Headache. 2013;53:644–55.

Article  PubMed  Google Scholar 

Matharu MS, Boes CJ, Goadsby PJ. Management of trigeminal autonomic cephalgias and hemicrania continua. Drugs. 2003;63:1637–77.

Article  CAS  PubMed  Google Scholar 

Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016;56:1093–106.

Article  PubMed  Google Scholar 

Burch R. Preventive migraine treatment. Continuum. 2021;27:613–32.

PubMed  Google Scholar 

Wu JW, Yang CP. 2022 Taiwan Guidelines for Preventive Treatment of Migraine. Acta Neurol Taiwan. 2022;31:164–202.

Google Scholar 

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of. Neurol Am Headache Soc Neurol 2012;78:1337–45.

CAS  Google Scholar 

Kowalska M, Prendecki M, Piekut T, Kozubski W, Dorszewska J. Migraine: Calcium Channels and Glia. Int J Mol Sci. 2021;22:2688.

Di Stefano V, Rispoli MG, Pellegrino N, Graziosi A, Rotondo E, Napoli C, et al. Diagnostic and therapeutic aspects of hemiplegic migraine. J Neurol Neurosurg Psychiatry. 2020;91:764–71.

Article  PubMed  Google Scholar 

Solomon GD, Steel JG, Spaccavento LJ. Verapamil prophylaxis of migraine. A double-blind, placebo-controlled study. JAMA. 1983;250:2500–2.

Article  CAS  PubMed  Google Scholar 

Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology. 2003;60:120–1.

Article  PubMed  Google Scholar 

Petersen AS, Barloese MCJ, Snoer A, Soerensen AMS, Jensen RH. Verapamil and cluster headache: still a mystery. a narrative review of efficacy, mechanisms and perspectives. Headache. 2019;59:1198–211.

Article  PubMed  Google Scholar 

Gabai IJ, Spierings EL. Prophylactic treatment of cluster headache with verapamil. Headache. 1989;29:167–8.

Article  CAS  PubMed  Google Scholar 

Jónsdóttir M, Meyer JS, Rogers RL. Efficacy, side effects and tolerance compared during headache treatment with three different calcium blockers. Headache. 1987;27:364–9.

Article  PubMed  Google Scholar 

Fotuhi M, Glaun B, Quan SY, Sofare T. Vestibular migraine: a critical review of treatment trials. J Neurol. 2009;256:711–6.

Article  PubMed  Google Scholar 

Pomes LM, Guglielmetti M, Bertamino E, Simmaco M, Borro M, Martelletti P. Optimising migraine treatment: from drug-drug interactions to personalized medicine. J Headache Pain. 2019;20:56.

Article  PubMed  PubMed Central  Google Scholar 

Cutrer FM, Moyer AM, Atkinson EJ, Wang L, Tian S, Wu Y, et al. Genetic variants related to successful migraine prophylaxis with verapamil. Mol Genet Genomic Med. 2021;9:e1680.

Busse D, Cosme J, Beaune P, Kroemer HK, Eichelbaum M. Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharm. 1995;353:116–21.

Article  CAS  Google Scholar 

Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, et al. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharm Ther. 2007;82:579–85.

Article  CAS  Google Scholar 

Kroemer HK, Gautier JC, Beaune P, Henderson C, Wolf CR, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharm. 1993;348:332–7.

Article  CAS  Google Scholar 

Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharm. 1999;47:545–52.

Article  CAS  Google Scholar 

Zhao LM, He XJ, Qiu F, Sun YX, Li-Ling J. Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects. Br J Clin Pharm. 2009;68:395–401.

Article  CAS  Google Scholar 

Borlak J, Walles M, Levsen K, Thum T. Verapamil: metabolism in cultures of primary human coronary arterial endothelial cells. Drug Metab Dispos. 2003;31:888–91.

Article  CAS  PubMed  Google Scholar 

Zhou Y, Ingelman-Sundberg M, Lauschke VM. Worldwide distribution of Cytochrome P450 Alleles: A meta-analysis of population-scale sequencing projects. Clin Pharm Ther. 2017;102:688–700.

Article  CAS  Google Scholar 

Amitriptyline [package insert]. Prinston, NJ: Sandoz Inc.; 2014.

PAMELOR® (nortriptyline) [package insert]. Hazelwood, MO: Mallinckrodt Pharmaceuticals; 2019.

EFFEXOR XR® (venlafaxine) [package insert]. Philadelphia, PA: Pfizer; 2021.

Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Müller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharm Ther. 2017;102:37–44.

Article  CAS  Google Scholar 

Jiang F, Kim HD, Na HS, Lee SY, Seo DW, Choi JY, et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes. Psychopharmacology. 2015;232:1899–909.

Article  CAS  PubMed  Google Scholar 

The Royal Dutch Pharmacists Association-Pharmacogenetics Working Group (DPWG). Dutch guidelines August 2019 update.

CALAN® SR (verapamil) [package insert]. New York, NY: Pfizer; 2019.

Fuhr U, Müller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S, et al. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharm. 2002;58:45–53.

Article  CAS  Google Scholar 

Benowitz NL, Peng M, Jacob P 3rd. Effects of cigarette smoking and carbon monoxide on chlorzoxazone and caffeine metabolism. Clin Pharm Ther. 2003;74:468–74.

Article  CAS  Google Scholar 

Bauer M, Karch R, Zeitlinger M, Philippe C, Römermann K, Stanek J, et al. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. J Cereb Blood Flow Metab. 2015;35:743–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eriksen MK, Thomsen LL, Olesen J. Sensitivity and specificity of the new international diagnostic criteria for migraine with aura. J Neurol Neurosurg Psychiatry. 2005;76:212–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kelman L. The aura: a tertiary care study of 952 migraine patients. Cephalalgia. 2004;24:728–34.

Article  CAS  PubMed  Google Scholar